PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

MiR-133b Affect the Proliferation and Drug Sensitivity in A549 Lung Cancer Stem Cells by Targeting PKM2.

Abstract It has been proven that miR-133b could inhibit cancer cell growth, the expression level of miR-133b was significant reduction in lung cancer tissue and serum of patients, and increase the radiation sensitivity of squamous cell carcinoma by targeting PKM2, but the exist mechanisms is not clear. The aim of this study is to explore the effect of miR-133b on proliferation in A549 lung cancer stem cells and drug sensitivity in DDP, and to explore the relationship between miR-133b and PKM2 gene, as well as the effect of cancer stem cells.
PMID
Related Publications

The effect and mechanism of microRNA-21 on cis-dichlorodiamineplatinum resistance in lung cancer cell strain.

miR-145 inhibits lung adenocarcinoma stem cells proliferation by targeting OCT4 gene.

Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.

MiR-133b regulates bladder cancer cell proliferation and apoptosis by targeting Bcl-w and Akt1.

Downregulation of PEBP4, a target of miR-34a, sensitizes drug-resistant lung cancer cells.

Authors

Mayor MeshTerms
Keywords
Journal Title zhongguo fei ai za zhi = chinese journal of lung cancer
Publication Year Start




PMID- 28641694
OWN - NLM
STAT- In-Process
DA  - 20170623
LR  - 20170623
IS  - 1999-6187 (Electronic)
IS  - 1009-3419 (Linking)
VI  - 20
IP  - 6
DP  - 2017 Jun 20
TI  - [MiR-133b Affect the Proliferation and Drug Sensitivity in A549 Lung Cancer Stem 
      Cells by Targeting PKM2].
PG  - 376-381
LID - 10.3779/j.issn.1009-3419.2017.06.02 [doi]
AB  - BACKGROUND: It has been proven that miR-133b could inhibit cancer cell growth,
      the expression level of miR-133b was significant reduction in lung cancer tissue 
      and serum of patients, and increase the radiation sensitivity of squamous cell
      carcinoma by targeting PKM2, but the exist mechanisms is not clear. The aim of
      this study is to explore the effect of miR-133b on proliferation in A549 lung
      cancer stem cells and drug sensitivity in DDP, and to explore the relationship
      between miR-133b and PKM2 gene, as well as the effect of cancer stem cells.
      METHODS: Using miRBase and miRNAMap database to sequence comparison miR-133b and 
      PKM2 gene. Using immune magnetic separation method to select the CD133+/CD34+
      lung cancer stem cells from A549 cells, and using flow cytometry to detect the
      purity. The expression of miR-133b mRNA was detected by real-time fluorescence
      quantitative PCR (qRT-PCR). Cell proliferation was detected by CCK8 assay. 15
      mug/mL DDP was treated to cells which was transfected with miR-133b, and
      apoptosis was detected by flow Cytometry at 0 h, 12 h, 24 h, 72 h. The expression
      of PKM2 protein was detected by Western blot. RESULTS: Gene binding site report
      that PKM2 gene may be the target gene of miR-133b; the results of flow cytometry 
      showed that the purity of CD133+/CD34+ stem cells was (92.15+/-4.27)%. qRT-PCR
      results showed that compared with the control group, after overexpression of
      miR-133b, miR-133b was up-regulated and miR-133b was down regulated after
      miR-133b inhibition (P<0.05). Compared with the control group, cell proliferation
      of miR-133b mimics group was significantly decreased (P<0.05), PKM2 protein
      levels were significantly lower (P<0.05); and cell proliferation of the miR-133b 
      inhibitor group and PKM2 level was increased (P<0.05). The apoptosis of miR-133b 
      mimics group was significantly higher than that of control group (P<0.05) after
      DDP treatment with 12 h. The expression of PKM2 protein in miR-133b mimics+DDP
      group was significantly lower than that in control group (P<0.05). CONCLUSIONS:
      Overexpression of miR-133b can inhibit the growth and proliferation of lung
      cancer stem cells by down regulating PKM2, and can enhance the sensitivity of
      lung cancer stem cells to DDP.
FAU - Mi, Yonghua
AU  - Mi Y
AD  - Department of Laboratory, Yongchuan Affiliated Hospital Chongqing Medical
      University, Chongqing 402160, China.
FAU - He, Miao
AU  - He M
AD  - Respiratory Medicine, Xindu District People's Hospital of Chengdu, Chengdu
      610500, China.
FAU - Liu, Beizhong
AU  - Liu B
AD  - Department of Laboratory, Yongchuan Affiliated Hospital Chongqing Medical
      University, Chongqing 402160, China.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhongguo Fei Ai Za Zhi
JT  - Zhongguo fei ai za zhi = Chinese journal of lung cancer
JID - 101126433
EDAT- 2017/06/24 06:00
MHDA- 2017/06/24 06:00
CRDT- 2017/06/24 06:00
AID - 10.3779/j.issn.1009-3419.2017.06.02 [doi]
PST - ppublish
SO  - Zhongguo Fei Ai Za Zhi. 2017 Jun 20;20(6):376-381. doi:
      10.3779/j.issn.1009-3419.2017.06.02.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>